Hjem › Kronisk myelomonocytisk leukemi › Texas
Kliniske studier for Kronisk myelomonocytisk leukemi i Texas
18 studier for Kronisk myelomonocytisk leukemi søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT03383575Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
- MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07033598Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- AIR Care, Dallas
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
RekruttererFase 2/3Frivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 11. aug. 2026 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 til 80 · Alle kjønn · Oppdatert 7. aug. 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 15 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT02727803Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT07128381A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mai 2026 · NCT04239157CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mai 2026 · NCT03896269A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT04140487A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
RekruttererFase 2
Alder 18 til 66 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 12 og eldre · Alle kjønn · Oppdatert 16. mar. 2026 · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. feb. 2026 · NCT06950034Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- MD Anderson Cancer Center, Huston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.